Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HOOKIPA PHARMA INC.

(HOOK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September

09/07/2021 | 10:01am EST

NEW YORK and VIENNA, Austria, Sept. 07, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and present at the following upcoming virtual investor conferences:

  • Morgan Stanley 19th Annual Global Healthcare Conference, September 9 – 10 and 13 – 15, 2021
    Fireside Chat: September 10, 8:45am ET
  • H.C. Wainwright 23rd Annual Global Investment Conference, September 13 – 15, 2021
    Presentation: September 13, 7:00am ET
  • 2021 Cantor Virtual Global Healthcare Conference, September 27 – 30, 2021
    Presentation: September 28, 8:00-8:30am ET in Track 7

Webcasts will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. Archived replays will be accessible for 30 days following each event.

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies that mobilize and amplify targeted T cells and antibodies, the body’s natural infection killers, to fight or prevent serious disease.

HOOKIPA is developing a broad pipeline of potential first-in-class arenaviral immunotherapies in oncology and infectious disease. We are leveraging our proprietary, versatile platform to engineer arenaviral therapeutics that induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies to a broad range of self and non-self antigens, including viral antigens, tumor-associated antigens and neoantigens. Our immunotherapies are designed to use either non-replicating or replicating viral vectors based on the target disease, with the potential to induce CD8+ T cell response levels previously not achieved by other immunotherapy approaches.

HOOKIPA’s pipeline includes ongoing clinical trials in Human Papilloma Virus 16-positive cancers and Cytomegalovirus, as well as preclinical research in prostate cancer, HIV and Hepatitis B. The latter two are in collaboration with Gilead Sciences, Inc.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact: 
  
MediaInvestors
Astrid van ErvenMatt Beck
Senior Manager - CommunicationsExecutive Director - Investor Relations
astrid.vanerven@hookipapharma.commatthew.beck@hookipapharma.com


Primary Logo


ę GlobeNewswire 2021
All news about HOOKIPA PHARMA INC.
11/12HOOKIPA Pharma to Participate in Upcoming Stifel 2021 Virtual Healthcare Conference
AQ
11/12Morgan Stanley Downgrades HOOKIPA Pharma to Equal-Weight From Overweight; Price Target ..
MT
11/11HC Wainwright Adjusts Price Target on Hookipa Pharma to $15 From $21, Keeps Buy Rating
MT
11/11HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights
AQ
11/10SVB Leerink Adjusts HOOKIPA Pharma PT to $10 From $28, Maintains Outperform Rating
MT
11/10JMP Securities Adjusts Price Target on HOOKIPA Pharma to $11 From $25, Maintains Market..
MT
11/10RBC Cuts PT on HOOKIPA Pharma to $17 From $24, Citing Program Prioritization, Timeline ..
MT
11/10HOOKIPA PHARMA INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
11/10HOOKIPA Pharma Reports Third Quarter 2021 Financial Results andRecent Highlights - Form..
PU
11/10HOOKIPA Pharma Reports Third Quarter 2021 Financial Results andáRecent Highlights
GL
More news
Analyst Recommendations on HOOKIPA PHARMA INC.
More recommendations
Financials (USD)
Sales 2021 18,7 M - -
Net income 2021 -76,1 M - -
Net cash 2021 89,9 M - -
P/E ratio 2021 -1,39x
Yield 2021 -
Capitalization 96,8 M 96,8 M -
EV / Sales 2021 0,37x
EV / Sales 2022 -0,56x
Nbr of Employees 123
Free-Float 78,9%
Chart HOOKIPA PHARMA INC.
Duration : Period :
HOOKIPA Pharma Inc. Technical Analysis Chart | HOOK | US43906K1007 | MarketScreener
Technical analysis trends HOOKIPA PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,23 $
Average target price 14,14 $
Spread / Average Target 338%
EPS Revisions
Managers and Directors
J÷rn Aldag Chief Executive Officer & Director
Thomas Lingelbach President
Reinhard Kandera Chief Financial Officer & Director
Jan G. J. van de Winkel Chairman
Igor Matushansky Chief Medical Officer & Global Head-Research
Sector and Competitors
1st jan.Capi. (M$)
HOOKIPA PHARMA INC.-70.87%97
JOHNSON & JOHNSON-0.92%410 501
ROCHE HOLDING AG16.39%337 091
PFIZER, INC.45.97%301 579
NOVO NORDISK A/S65.17%243 741
ELI LILLY AND COMPANY46.91%224 871